CompoAtlas

AMINCIL DRAINEUR Ventre Plat

Food supplement declared in France, declaration No 2023-9-1197, decision dated 21 September 2023

AMINCIL DRAINEUR Ventre Plat (LABORATOIRE LESCUYER) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 2 rules of use apply to its ingredients (limits and warnings).

Brand
LABORATOIRE LESCUYER
Food business operator placing the product on the market
LABORATOIRE LESCUYER (SAS)
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Bâton / batônnet / stick
Daily dose
1 stick par jour
Directions for use
Verser le contenu du stick dans 250 à 500 ml d’eau et mélanger jusqu’à dispersion complète.
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Allergie aux dérivés salicylés, Femmes enceintes, Sous anticoagulants
Objectives stated by the manufacturer (these are not authorised claims)
Minceur / Ventre plat
Flavourings
Thé pêche

Declaration 135030, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Carum carvi L.FruitExtrait sec aqueux400 mg
Filipendula ulmaria (L.) Maxim.Sommités fleuriesExtrait sec aqueux250 mg
Paullinia cupana KunthGraineExtrait sec aqueux25 mg
Solidago virgaurea L.Parties aériennesExtrait sec aqueux15 mg
Foeniculum vulgare Mill.FruitExtrait sec aqueux11 mg
Taraxacum campylodes G.E.HaglundFeuilleExtrait sec aqueux4.8 mg

Other active ingredients

NamePer day
Caféinenot declared
Fibres solubles de maïsnot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
D-biotineBiotine (vitamine B8)pas de limite (données insuffisantes)dose annulée par le Conseil d'État en 2011
NicotinamideNicotinamide (vitamine B3)900 mg54 mg
Citrate de potassiumPotassiumpas de limite (données insuffisantes)80 mg
Chlorhydrate de thiamineVitamine B1 (thiamine)pas de limite (données insuffisantes)dose annulée par le Conseil d'État en 2011
RiboflavineVitamine B2 (riboflavine)pas de limite (données insuffisantes)dose annulée par le Conseil d'État en 2011
Acide L-ascorbiqueVitamine Cpas de limite (données insuffisantes)180 mg

Additives

E960

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Réservé à l’adulte. Déconseillé aux femmes enceintes et qui allaitent. Déconseillé aux personnes allergiques aux dérivés salicylés. Déconseillé aux personnes sous traitement anticoagulant.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Carum carvi L.
    Read the warning, when it applies and the studies cited

    Caraway - Carum Carvi

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen (ESCOP 2003).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have acute abdominal pain (ESCOP 2003).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Brinker 2010; ESCOP 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 31 January 2025

  • Foeniculum vulgare Mill.
    Read the warning, when it applies and the studies cited

    BITTER FENNEL- FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Essential oil and Tincture.

    Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 November 2024

    SWEET FENNEL -FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 November 2024

  • Taraxacum campylodes G.E.Haglund
    Read the warning, when it applies and the studies cited

    DANDELION - TARAXACUM OFFICINALE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder or an intestinal obstruction (Brinker 2010; Godfrey et al. 2010; ESCOP 2003; Bradley 1992).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Constipation, Flushing of the urinary tract, Indigestion, and Loss of appetite.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Applies to products providing 10 g or more of dried leaf or dried root or dried whole plant, per day or 10 mL or more of juice, per day.

    Do not use if you have diabetes or a blood pressure, kidney or cardiovascular disorder (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you are taking heart medications or other products containing diuretics (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 25 July 2025

  • Caféine
    Read the warning, when it applies and the studies cited

    CAFFEINE

    Route of administration: Oral (Higdon and Frei 2006)

    Cautions and warnings

    Applies to products providing 100 mg to 400 mg caffeine, per day1.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Applies to products providing more than 300 mg caffeine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing 400 mg or more caffeine, per day.

    When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Applies to products providing more than 400 mg caffeine per day.

    Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing 200 mg or more caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing more than 400 mg caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: All products except those making a diuretic claim1.

    When using this product diuretic effect may occur.

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : LABORATOIRE LESCUYER

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2023. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line